Search | Clinical Trials Finder

Conditions: Herpes Labialis
Interventions: Squaric Acid solution, Placebo solution; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Herpes Zoster
Interventions: Herpes Zoster Vaccine GSK1437173A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 8,687 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 37
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Herpes Genitalis
Interventions: valacyclovir hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 3
States / cities: Altamonte Springs, Florida • Chicago, Illinois • Boston, Massachusetts

Conditions: Postherpetic Neuralgia
Interventions: Retigabine, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 36 more

Conditions: Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions: REN-1654; Drug
Lead sponsor: Renovis; Industry
Eligibility: 55 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 16
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more

Conditions: High-risk Prostate Cancer, Prostate Cancer
Interventions: HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy; Drug · Radiation · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kaposi's Sarcoma, Herpesviridae Infection
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 20,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions: Posoleucel (ALVR105); Biological
Lead sponsor: AlloVir; Industry
Eligibility: 1 Year and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more

Conditions: Herpes Simplex Virus 2
Interventions: Not listed
Lead sponsor: Focus Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Burbank, California

Conditions: Herpes Zoster, Postherpetic Neuralgia
Interventions: ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir; Drug
Lead sponsor: aRigen Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Beverly Hills, California • Encino, California • Vista, California + 5 more

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more

Conditions: HIV Infections
Interventions: Zidovudine, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 8
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Zoster Vaccine Recombinant, Adjuvanted; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Zoster
Interventions: Herpes Zoster Vaccine GSK1437173A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Long Beach, California • San Francisco, California • Orlando, Florida + 2 more

Conditions: Genital Herpes Simplex Type 2
Interventions: VCL-HB01, VCL-HM01, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Pain
Interventions: Oxymorphone; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Herpes Zoster, Herpes Zoster Vaccine
Interventions: Herpes Zoster Vaccine GSK1437173A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 7,539 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more

Conditions: Herpes Zoster, Shingles, Genital Herpes
Interventions: Valacyclovir Hydrochloride; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV Infections
Interventions: Varicella Virus Vaccine (Live); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Months to 8 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 25
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 16 more

Conditions: Herpes Simplex
Interventions: GSK208141, Havrix (investigational formulation), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 5,960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more

Conditions: Healthy Volunteers
Interventions: HSV529, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions: TGX-007, Valaciclovir; Drug
Lead sponsor: Trogenix ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Herpes Zoster
Interventions: HZ/su vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 3,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more

Conditions: Kidney Transplant; Complications
Interventions: SHINGRIX; Biological
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Atlanta, Georgia

Search by objective public record fields.

Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Solid Organ Transplant SHINGRIX